United States Patent 7,658,945: Claim Scope, Validity Risks, Exclusivity and Zolpidem Patent Landscape
U.S. Patent No. 7,658,945 covers low-dose, rapidly dissolving zolpidem compositions intended for absorption through the oral mucosa. Its core inventive combination is narrow: 1–5 mg zolpidem, carbonate and bicarbonate buffers in a specified weight ratio, saliva pH of at least about 7.8, and at least 75% dissolution in the oral cavity within about 10 minutes. The patent has both method-of-treatment claims and composition claims.[1]
The strongest commercial relevance is to sublingual zolpidem products such as Edluar and Intermezzo. The strongest infringement defenses are likely to concern buffer identity, buffer ratio, pH measurement, dissolution testing, oral-mucosal absorption, and whether the accused product falls within the 1–5 mg dosage range.
What does U.S. Patent 7,658,945 protect?
The patent protects two related subject matter groups:
- A method of treating insomnia by administering the claimed zolpidem composition.
- A pharmaceutical composition with the claimed zolpidem, buffer, pH and dissolution characteristics.
| Claim group |
Claims |
Principal subject matter |
| Method claims |
1–13, 24 |
Treating insomnia with a 1–5 mg solid zolpidem composition absorbed through oral mucosa |
| Composition claims |
14–23, 25–26 |
Solid or solid-capable composition having specified formulation and performance characteristics |
| Dosage-form limitations |
12–13, 19–20 |
Lozenge or tablet |
| Excipient limitations |
2, 18 |
Binder and disintegrating agent |
| Oral-administration limitations |
6–7 |
Sublingual, buccal, gingival, palatal or lip mucosa |
| Pharmacokinetic limitations |
8–9, 24–26 |
Peak concentration or bloodstream delivery within 20–30 minutes |
| Buffer limitations |
10–11, 16–17, 21–23 |
Narrower ratios and defined carbonate or bicarbonate species |
The patent does not broadly cover every zolpidem tablet, every orally disintegrating tablet, or every sublingual zolpidem product. The independent claims require the full combination of structural and functional limitations.
What are the independent claims in U.S. Patent 7,658,945?
Claim 1: Method of treating insomnia
Claim 1 requires all of the following:
- Administration to a subject for treatment of insomnia.
- A solid pharmaceutical composition.
- Zolpidem in an amount of about 1–5 mg.
- A carbonate buffer.
- A bicarbonate buffer.
- Oral-mucosal absorption of zolpidem.
- A carbonate:bicarbonate weight ratio of about 1:1 to about 1:10.
- Salivary pH raised to about 7.8 or greater.
- At least 75% dissolution in the oral cavity within about 10 minutes or less.
This is a cumulative limitation structure. An accused product that satisfies the dose, dosage form and sublingual route but lacks the claimed carbonate/bicarbonate system would not literally meet claim 1.
Claim 14: Pharmaceutical composition
Claim 14 requires:
- About 1–5 mg zolpidem.
- A carbonate buffer.
- A bicarbonate buffer.
- A carbonate:bicarbonate ratio of about 1:1 to about 1:10.
- Adaptation to raise saliva pH to about 7.8 or greater.
- Adaptation to dissolve at least 75% within about 10 minutes or less in the oral cavity.
Claim 14 is broader in form than the method claims because it does not expressly require treatment of insomnia or actual administration. It remains narrow because the claimed composition must possess, or be designed to possess, specific pH and dissolution performance.
How do the dependent claims narrow the patent scope?
Claims 2–13 and 15–26 create narrower positions around the core formulation.
Buffer-ratio limitations
Claims 10 and 16 narrow the ratio to approximately 1:1 through 1:5. Claims 11 and 17 narrow it further to approximately 1:1 through 1:2.
These claims are commercially significant because a product outside the 1:1 to 1:2 range may avoid the narrowest claims while remaining within claim 1 or claim 14 if it falls within the broader 1:1 to 1:10 range.
Dosage-form limitations
Claims 12, 13, 19 and 20 cover lozenges and tablets. Claim 1 itself requires a solid composition but does not limit the product to a tablet or lozenge. A fast-dissolving film, wafer or other solid dosage form could potentially fall within the independent claims if all other limitations are met.
Oral-mucosal route
Claim 6 specifies sublingual administration. Claim 7 identifies five oral-mucosal sites:
- Sublingual mucosa
- Buccal mucosa
- Gingival mucosa
- Palatal mucosa
- Lining of the lips
A product swallowed immediately without meaningful oral-mucosal absorption would face a substantial challenge under the method claims.
Pharmacokinetic limitations
Claim 8 requires a mean peak plasma concentration of about 20–100 ng/mL within about 30 minutes. Claims 9 and 24 require a therapeutically effective amount to enter the bloodstream within 30 or 20 minutes, respectively. Claims 25 and 26 apply comparable delivery requirements to the composition claims.
These claims add clinical or pharmacokinetic limitations that may be difficult to prove from commercial-product testing alone. They also create potential disputes over:
- The meaning of “mean peak plasma concentration.”
- The population tested.
- Whether the result must occur in every patient or only in a study average.
- The analytical method and sampling schedule.
- The meaning of “therapeutically effective amount.”
- Whether the bloodstream-delivery limitation is inherent or merely intended use.
Excipient limitations
Claims 2 and 18 add a binder and a disintegrating agent. These claims are narrow because many solid oral dosage forms contain both excipient classes, but the patent still requires the underlying carbonate/bicarbonate and zolpidem limitations.
Defined buffer species
Claims 21 and 22 list alternative carbonate and bicarbonate salts. Claim 23 specifically covers desiccant-coated sodium bicarbonate. The listed carbonate salts include sodium, potassium, calcium, ammonium and magnesium carbonate. The listed bicarbonates include corresponding sodium, potassium, calcium, ammonium and magnesium species.
The species claims may be useful against formulation designs that attempt to avoid infringement by changing the counterion while preserving the claimed pH and dissolution behavior.
What formulation characteristics are protected?
The patent protects formulation performance, not merely ingredient identity.
| Limitation |
Scope |
| Zolpidem dose |
About 1–5 mg |
| Carbonate/bicarbonate ratio |
About 1:1 to 1:10 by weight |
| Narrow ratio |
About 1:1 to 1:5 |
| Narrowest ratio |
About 1:1 to 1:2 |
| Salivary pH |
About 7.8 or greater |
| Dissolution |
At least 75% within about 10 minutes or less |
| Faster dissolution |
About 1–3 minutes or about 2–3 minutes |
| Route |
Oral mucosa, including sublingual and buccal routes |
| Dosage form |
Solid composition, tablet or lozenge |
| Delivery |
Therapeutically effective bloodstream delivery within 20–30 minutes |
The pH and dissolution requirements are particularly important. A formulation may contain both carbonate and bicarbonate but avoid a claim if it does not raise salivary pH to the claimed level or does not meet the oral-cavity dissolution threshold.
How strong is the patent estate based on the claim structure?
The estate has moderate technical specificity and potentially significant design-around exposure.
Strengths
- Independent claims combine composition, dose, route and performance limitations.
- The carbonate/bicarbonate system provides a concrete formulation signature.
- Claims cover both treatment methods and compositions.
- Dependent claims preserve narrower positions around dosage forms, buffer ratios and chemical species.
- Sublingual and buccal delivery are expressly addressed.
- Rapid dissolution and bloodstream delivery align with the commercial rationale for sublingual zolpidem.
Weaknesses
- The claims depend heavily on functional testing.
- “About” ranges may generate claim-construction disputes.
- The claims do not specify a single test method for salivary pH or dissolution.
- Oral-cavity dissolution may vary with saliva volume, agitation, temperature, placement and test subject.
- “Adapted to” language in claim 14 and related claims may be challenged as an intended-capability limitation unless supported by structural features.
- The independent claims may be vulnerable if the specification does not enable the full range of carbonate and bicarbonate salts, ratios, doses and dosage forms.
- A product using a different buffering system, a noncarbonate alkalizing agent, or a formulation that dissolves after swallowing may have a credible noninfringement position.
What generic entry risks exist for zolpidem products?
A conventional swallowed zolpidem tablet is less likely to fall within these claims because the patent requires oral-mucosal absorption and a carbonate/bicarbonate system. A generic sublingual or buccal zolpidem product presents a higher risk if it has:
- A 1.75–5 mg zolpidem dose.
- Both carbonate and bicarbonate salts.
- A 1:1 to 1:10 weight ratio.
- Rapid dissolution in the mouth.
- A salivary pH of at least about 7.8.
- Evidence of transmucosal absorption.
A generic applicant could pursue several design-around strategies:
- Use a buffer system without both carbonate and bicarbonate.
- Use an alternative alkalizing agent.
- Use a dose below 1 mg or above 5 mg, where clinically and regulatorily appropriate.
- Use a swallowed immediate-release tablet.
- Avoid sublingual or buccal absorption.
- Formulate the product to dissolve more slowly in the oral cavity.
- Use a different solid dosage form and demonstrate that the claimed performance is absent.
These strategies may affect bioequivalence and product labeling. A design that avoids the patent but changes the absorption profile could create FDA regulatory challenges.
How does the patent compare with Edluar and Intermezzo?
Edluar and Intermezzo are sublingual zolpidem products, making them the closest commercial comparators.
| Product |
Active ingredient |
Sublingual route |
Typical dose range |
Patent relevance |
| Edluar |
Zolpidem tartrate |
Yes |
5 mg and 10 mg strengths |
5 mg strength is within the claimed dose range; formulation-specific analysis is required |
| Intermezzo |
Zolpidem tartrate |
Yes |
1.75 mg and 3.5 mg strengths |
Both strengths fall within the claimed 1–5 mg range; buffer and performance limitations remain decisive |
| Conventional zolpidem tablets |
Zolpidem tartrate |
No |
Commonly 5 mg and 10 mg |
Generally less exposed to oral-mucosal limitations |
| Oral spray or other rapid-delivery products |
Zolpidem or zolpidem tartrate |
Variable |
Product-specific |
Exposure depends on solid dosage-form and buffer limitations |
The dose overlap alone does not establish infringement. The relevant question is whether the commercial formulation contains the claimed carbonate and bicarbonate system and meets the claimed pH and dissolution characteristics. FDA labeling identifies active and inactive ingredients, but it may not disclose every formulation parameter needed to resolve infringement.[2][3]
What is the Orange Book status of U.S. Patent 7,658,945?
A patent’s presence in the U.S. Patent and Trademark Office database does not establish that it is listed in the FDA Orange Book. Orange Book listing is product-specific and depends on submission by the NDA holder and FDA listing practices.[4]
For a listed patent to create a Paragraph IV barrier, it must be associated with the relevant reference-listed drug. The analysis therefore requires separate review of:
- The Orange Book patent listing for Edluar.
- The Orange Book patent listing for Intermezzo.
- The listed claims identified by the NDA holder.
- Any delisting, expiration or withdrawn-listing events.
- Whether the patent claims the approved drug substance, formulation or method of use.
The supplied claims alone do not establish Orange Book listing, Paragraph IV certification history or a current regulatory stay.
When does U.S. Patent 7,658,945 lose exclusivity?
The claims do not state the patent’s expiration date. Patent term is determined from the application’s earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any other applicable term events.[5]
The issue date, February 9, 2010, is not itself the expiration-date determinant. A definitive exclusivity analysis must distinguish:
- Statutory patent term.
- Patent-term adjustment.
- Patent-term extension, if any.
- Terminal disclaimer.
- Continuation or divisional patents.
- Separate Orange Book-listed patents covering the same product.
- FDA regulatory exclusivity, which is independent of patent term.
For small-molecule zolpidem products, biosimilar exclusivity is not relevant. A competing applicant would generally use an abbreviated new drug application, not a biosimilar application. The principal regulatory litigation mechanism would be an ANDA Paragraph IV certification if the patent is listed against the reference product.[4]
What Paragraph IV and patent litigation risks apply?
A Paragraph IV challenge would likely focus on one or more of these issues:
Noninfringement
The applicant could argue that its product:
- Contains no carbonate buffer.
- Contains no bicarbonate buffer.
- Uses a ratio outside the claimed range.
- Does not raise saliva pH to 7.8 or greater.
- Does not dissolve at least 75% within 10 minutes.
- Does not rely on oral-mucosal absorption.
- Uses a dose outside the 1–5 mg range.
Invalidity
Potential validity challenges include:
- Anticipation by earlier sublingual zolpidem formulations.
- Obviousness based on combining low-dose zolpidem with known oral buffers.
- Lack of written description for the full chemical and functional ranges.
- Lack of enablement across all listed carbonate and bicarbonate salts.
- Indefiniteness involving “about,” “adapted to,” “therapeutically effective amount” and test conditions.
Method-claim enforcement
Method claims may be harder to enforce against an ANDA product if the proposed label does not instruct the patented method. The composition claims may present a more direct product-based theory if the formulation itself satisfies the limitations.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are lower than formulation barriers for a conventional tablet but increase for a rapidly dissolving sublingual product. A competing manufacturer would need to control:
- Uniform distribution of low-dose zolpidem.
- Carbonate and bicarbonate ratio.
- Moisture protection, especially for bicarbonate.
- Tablet hardness and friability.
- Rapid oral disintegration.
- Taste and mucosal tolerability.
- Stability of the buffering system.
- Consistent salivary pH performance.
- Reproducible transmucosal absorption.
Claim 23’s reference to desiccant-coated sodium bicarbonate indicates that moisture control may have been a relevant formulation concern. A manufacturer could avoid that specific claim by using another bicarbonate form, but claims 14, 16, 17 and 22 could remain relevant if the alternative still satisfies their limitations.
Key Takeaways
- U.S. Patent 7,658,945 is directed to fast-dissolving, low-dose oral-mucosal zolpidem.
- The central technical limitation is the combined carbonate/bicarbonate buffer system.
- The broadest stated ratio is approximately 1:1 to 1:10 by weight.
- The patent also requires salivary pH of about 7.8 or greater and at least 75% oral-cavity dissolution within about 10 minutes.
- Sublingual products in the 1–5 mg range present the greatest technical overlap.
- Conventional swallowed zolpidem tablets face materially lower exposure under the supplied claims.
- The claims contain multiple potential validity and claim-construction pressure points.
- A biosimilar pathway is irrelevant because zolpidem is a small molecule.
- Orange Book listing, Paragraph IV status, litigation and expiration cannot be established from the claim text alone.
- Patent term must be analyzed separately from FDA regulatory exclusivity and from other patents covering Edluar or Intermezzo.
FAQs
Does a 5 mg sublingual zolpidem tablet automatically infringe U.S. Patent 7,658,945?
No. The product must also satisfy the carbonate/bicarbonate, ratio, salivary-pH, dissolution and oral-mucosal absorption limitations.
Can a zolpidem product avoid the patent by using only sodium bicarbonate?
Potentially. The independent claims require both a carbonate buffer and a bicarbonate buffer. The product would still require analysis under the doctrine of equivalents and any other relevant patents.
Are Edluar and Intermezzo covered by this patent?
Their sublingual route and low-dose strengths create potential overlap. Coverage cannot be determined from dose and route alone because the claimed buffer and performance limitations must also be met.
Does a patent expiration automatically permit generic launch?
No. Generic launch also depends on other unexpired patents, Orange Book listings, regulatory exclusivity, litigation settlements and any applicable court order.
Is a rapidly dissolving oral film covered by the claims?
Possibly. The claims generally require a solid pharmaceutical composition, not expressly a tablet or lozenge in every independent claim. The film would need to satisfy the remaining ingredient, ratio, pH, dissolution and absorption limitations.
References
- United States Patent No. 7,658,945, claims 1–26. U.S. Patent and Trademark Office.
- U.S. Food and Drug Administration. (n.d.). Edluar: Zolpidem tartrate sublingual tablets prescribing information.
- U.S. Food and Drug Administration. (n.d.). Intermezzo: Zolpidem tartrate sublingual tablets prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension guidance.
